Abstract
Japan’s Astellas Pharma has agreed to buy Iveric Bio, a developer of treatments for retinal diseases, for about $5.9 billion. Iveric’s lead product is avacincaptad pegol, a protein inhibitor that may slow the progression of geographic atrophy, an advanced form of age-related macular degeneration. The US Food and Drug Administration accepted Iveric’s new drug application for the molecule in February, and Astellas expects a decision on it by Aug. 19.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
